SCHEMBL2691682

SCHEMBL2691682

Cc1[nH]cnc1-c1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.56
NPY5R Q15761 2/20 0.51
CYP3A4 P08684 3/20 0.49
CYP2E1 P05181 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2B6 P20813 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 1/20 0.48
QPCT Q16769 1/20 0.47
QPCTL Q9NXS2 1/20 0.47
ALK Q9UM73 1/20 0.47
MAP2K4 P45985 1/20 0.46
PTGS2 P35354 2/20 0.46
PTGS1 P23219 1/20 0.46
IDO1 P14902 1/20 0.44
LRRK2 Q5S007 1/20 0.44
PIM1 P11309 3/20 0.43
PIM3 Q86V86 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8002000 0.79 KDM4E (0.61) CYP3A4ALDH1A1IDO1KDM4EMAPT
SCHEMBL2821330 0.78 CYP2A6 (0.47) CYP2A6NPY5RCYP3A4CYP2E1CYP2D6
SCHEMBL7295129 0.77 MAPK14 (0.51) CYP3A4KDM4ELMNAMAPT
SCHEMBL27674566 0.75 CYP11B1 (0.49) CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9
SCHEMBL6601244 0.72 MAPK14 (0.68) NPY5RCYP3A4QPCTQPCTLIDO1
SCHEMBL7092910 0.72 CYP2A6 (0.67) CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6
SCHEMBL18818721 0.72 CYP2A6 (0.67) CYP2A6NPY5RCYP3A4CYP2E1CYP2D6
SCHEMBL3613457 0.72 CYP2A6 (1.00) CYP2A6NPY5RCYP3A4CYP2E1CYP2D6
SCHEMBL2689052 0.71 NPY5R (0.69) CYP2A6NPY5RCYP3A4CYP2E1CYP2C9
SCHEMBL4866745 0.71 PIK3CD (0.43) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104710420-B Azabicyclic formula compound or its salt, containing its medicine, compositions and application 大鹏药品工业株式会社 2016-07-27 CN disclosed
US-9273045-B2 Azabicyclo compound and salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-03-01 US disclosed
CN-102471335-B Azanebicyclic compound or salt thereof TAIHO PHARMACEUTICAL CO.,LTD. (JP) 2015-09-30 CN disclosed
CN-104710420-A Azabicyclo compound and salt thereof, medication and composition containing same, and application thereof TAIHO PHARMACEUTICAL CO LTD 2015-06-17 CN disclosed
EP-2452940-B1 AZABICYCLO COMPOUND AND SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2014-12-17 EP disclosed
US-20140303162-A1 AZABICYCLO COMPOUND AND SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-10-09 US disclosed
US-8779142-B2 Azabicyclo compound and salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-07-15 US disclosed
CN-102471335-A Azanebicyclic compound or salt thereof TAIHO PHARMACEUTICAL CO LTD 2012-05-23 CN disclosed
EP-2452940-A1 AZABICYCLO COMPOUND AND SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2012-05-16 EP disclosed
US-20120108589-A1 AZABICYCLO COMPOUND AND SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-05-03 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
EP-1618119-A2 PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS CHIRON CORPORATION (US) 2006-01-25 EP disclosed
US-20050009764-A1 Pyridyl substituted ketolide antibiotics CHIRON CORPORATION (US) 2005-01-13 US disclosed
WO-2004096822-A2 PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS CHIRON CORPORATION (US) 2004-11-11 WO disclosed
US-6756359-B2 ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS CHIRON CORPORATION 2004-06-29 US disclosed
EP-1404693-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2004-04-07 EP disclosed
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity CHU DANIEL (US) 2003-07-03 US disclosed
WO-2003004509-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009764-A1 Pyridyl substituted ketolide antibiotics PKLR, KHK, PGD CYP2A6 57/4885NPY5R 1184/4885CYP3A4 30/4885
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity MRPL21, CYP51A1, CEL CYP2A6 68/4885NPY5R 2767/4885CYP3A4 120/4885
US-20140303162-A1 AZABICYCLO COMPOUND AND SALT THEREOF HSP90AB1, HSP90AB2P, HSP90AA1 CYP2A6 3058/4885NPY5R 438/4885CYP3A4 2098/4885
US-20120108589-A1 AZABICYCLO COMPOUND AND SALT THEREOF HSP90AB1, HSP90AB2P, HSP90AA1 CYP2A6 3058/4885NPY5R 438/4885CYP3A4 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.